Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
|Slideshows|February 12, 2020
4 Factors That Play Pivotal Roles in Alzheimer Disease Progression
Author(s)Gjumrakch Aliev, MD, PhD
At present there are no treatments to stop or delay underlying disease progression. Current prevalent therapies help to mask the symptoms, but they do not solve underlying causes. A fundamental premise for effective treatment is to make a diagnosis of Alzheimer disease at the earliest stage.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5